The Ligand Pharmaceuticals Inc. (LGND) Upgrade to Hold by The Zacks Investment Research

Ligand’s Captisol formulation technology has resulted in partnerships with … The biotechnology company reported $0.62 earnings per share for the …

Advertisements
The Ligand Pharmaceuticals Inc. (LGND) Upgrade to Hold by The Zacks Investment Research

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s